4 completed, 2 active not recruiting, 2 recruiting. 6 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 2, Recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Stage IV Bladder Urothelial Carcinoma AJCC v7: new trials by email Literature Review of Stage IV Bladder Urothelial Carcinoma AJCC v7 trials Research Report on Stage IV Bladder Urothelial Carcinoma AJCC v7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 992 | 2024-02-02 | 2026-10-26 |
| Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo Nivolumab, Radiation - Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 20 | 2018-04-24 | 2023-08-04 |
| Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations Sapanisertib - Locally Advanced Bladder Urothelial Carcinoma, Metastatic Transitional Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 17 | 2017-08-24 | 2026-07-31 |
| Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer Berzosertib, Cisplatin, Gemcitabine Hydrochloride - Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 87 | 2017-01-31 | 2025-03-03 |
| Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery Eribulin Mesylate, Gemcitabine Hydrochloride - Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 26 | 2014-12-11 | 2019-12-16 |
| Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm | Recruiting | University of Washington | 1500 | 2009-08-01 | 2026-08-06 | |
| Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Bevacizumab, Cisplatin, Gemcitabine Hydrochloride - Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 506 | 2009-07-15 | 2026-06-24 |
| Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study - Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 171 | 2006-10-23 | 2026-09-09 |
Carcinoma, Transitional Cell (3) · Prostatic Neoplasms (2) · Ureteral Neoplasms (2) · Urethral Neoplasms (2) · Urinary Bladder Neoplasms (2)
Neoplasms (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Neoplasms by Site (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Urologic Diseases (4) · Urologic Neoplasms (4) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Genital Diseases (2) · Genital Diseases, Male (2) · Genital Neoplasms, Male (2)
Gemcitabine (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2) · Disulfides (2) · Immunoglobulin G (2) · Nivolumab (2) · Platinum (2) · eribulin (2) · Bevacizumab (1) · Cell-Free Nucleic Acids (1) · Circulating Tumor DNA (1) · Cystoscopy (1) · Magnetic Resonance Spectroscopy (1) · Radiation (1) · Specimen Handling (1)
National Cancer Institute (NCI) (6) · Barbara Ann Karmanos Cancer Institute (1) · University of Washington (1)
United States (8) · Canada (2) · Puerto Rico (1)
David I Quinn (1) · Jonathan E Rosenberg (1) · Joseph W Kim (1) · Matthew D Galsky (1) · Robert B. Montgomery (1) · Sarmad Sadeghi (1) · Sumanta K Pal (1) · Ulka N. Vaishampayan, M.D. (1)
PMID 31390274, PMID 33989025, PMID 34436521, PMID 40256659, PMID 40591902
N01CM00038 (3), U10CA180821 (2), UM1CA186717 (2), N01CM00071 (1), N01CM62201 (1), N01CM62209 (1), P30CA033572 (1), P30CA093373 (1), P50CA097186 (1), U01CA062505 (1), U10CA031946 (1), UM1CA186689 (1), UM1CA186690 (1), UM1CA186705 (1)